Ginkoflav Med 80 mg, 60 capsules — Made in Poland — Free Delivery

Ginkoflav Med by Olimp Laboratories contains quantified dry extract of ginkgo biloba leaves, which dilates blood vessels, improves blood flow in the brain and reduces platelet aggregation. The active substances of the ginkgo leaf extract are flavone glycosides, ginkgolides and bilobalide. Ginkoflav Med can be used to improve cognitive functions in the elderly (mental impairment and age-related memory impairment), and also to help improve the quality of life in mild dementia. The product is intended for use in adults.

For the improvement of cognitive functions in the elderly (mental impairment and age-related memory impairment), as an auxiliary to improve the quality of life in mild dementia. The product is intended for use in adults.

Each capsule contains 80 mg of quantified dry extract from Ginkgo biloba L. leaves, folium (35-67: 1), corresponding to: 17.6-21.6 mg of flavonoids in terms of flavone glycosides; 2.2-2.7 mg of ginkgolides A, B and C; 2.1-2.6 mg of bilobalide. Extraction solvent: acetone 65% (v / v). excipients, microcrystalline cellulose, magnesium stearate. Capsule shell: gelatin, titanium dioxide (E 171), purified water.

Improvement of cognitive functions in the elderly.

Adults and the elderly: 1 capsule 3 times a day. Oral use. The capsule should be washed down with liquid. Basic therapy should last at least 8 weeks. If after 3 months there is no improvement or the patient feels worse, see a doctor.

The product is not intended for use in children and adolescents. Hypersensitivity to the active substance or to any of the excipients.

Do not store above 25ºC.

The frequency of adverse reactions is defined as: Very common (1/10) Common (1/100 to <1/10) Uncommon (1 / 1,000 to <1/100) Rare (1 / 10,000 to <1 / 1,000) ) Very rare (≤1 / 10,000) not known (frequency cannot be estimated from the available data) Gastrointestinal disorders common: vomiting, nausea, abdominal pain, diarrhea Nervous system disorders very common: headache common: dizziness Not known: hypersensitivity reactions (anaphylactic shock) Skin and subcutaneous tissue disorders Not known: cutaneous hypersensitivity reactions such as erythema, edema, pruritus, rash Reporting of suspected adverse reactions It is important to report suspected adverse reactions after authorization of the medicinal product.

Since interactions with the medicinal products listed below cannot be ruled out, special care should be taken when administering Ginkoflav Med. The effect of these drugs may be enhanced when used concomitantly with anticoagulants (e.g. acenocoumarol and warfarin) or antiplatelet drugs (e.g. clopidogrel, acetylsalicylic acid and other NSAIDs). The available studies do not indicate any interaction with warfarin, however, appropriate monitoring is recommended when initiating Ginkgo biloba therapy, ending this therapy, changing the dosage or changing the product containing ginkgo biloba extract. Interaction studies with talinolol indicate that Ginkgo biloba may inhibit P-glycoprotein (P-gp) in intestinal cells. This may result in an increase in the availability of drugs that are significantly transported by P-gp in the gut, such as dabigatran. Caution is advised when using dabigatran and ginkgo biloba extract simultaneously. An interaction study with nifedipine suggested that ginkgo biloba extract may increase the maximum blood concentration (cmax) of this drug. Some study participants experienced a twofold increase in the peak concentration of nifedipine, leading to dizziness and an increase in symptoms such as hot flush. Concomitant use of ginkgo biloba extract and efavirenz products is not recommended. Efavirenz plasma concentrations may be decreased due to induction of the enzyme CYP3A4.